This post was originally published on this site
Over the summer the company reported strong results from an early-stage study for its experimental antibody therapy CDX-0159. Then last month, the company announced that it had initiated dosing in the first cohort of a phase I study evaluating the drug.
The company appears to have a solid balance sheet as it had $164 million in cash at the end of the last quarter compared to only $1 million in long-term debt. In terms of growth, sales are up 90.7% over the past year and are expected to soar 212.8% year over year in the current quarter leading to a Growth Grade of B in our POWR Ratings system.
